As an alternative therapeutic approach for metastatic ccRCC, preliminary data have shown a better response with a cell line-derived xenograft with a BAP1-mutated ccRCC cell line, 769-P, when treated with the oncolytic vaccinia virus (JX-594) (Park et al., 2025). This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.